BCTX BriaCell Therapeutics Corp.
Healthcare$3.42-2.01%ClosedMarket Cap: $6.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.32
P/S
0.00
EV/EBITDA
0.76
DCF Value
$4.27
FCF Yield
-466.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-166.3%
ROA
-88.2%
ROIC
-100.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $0.00 | -Infinity% | $-7.7M | $-7.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.7M | $-11.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-11.7M | $-11.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-37.7M | $-36.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-8.7M | $-8.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.6M | $-9.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-7.2M | $-8.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.0M | $-1.7M | $— | — |
| FY null | $0.00 | NaN% | $-46.3M | $-6.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.6M | $2.3M | $— | — |
| Q2 2024 | $0.00 | -Infinity% | $-13.3M | $-15.3M | $-143.32 | — |
| Q1 2024 | $0.00 | -Infinity% | $-11.4M | $8.1M | $-100.18 | — |